Natalizumab in the pediatric MS population: results of the Italian registry

Angelo Ghezzi1*, Lucia Moiola2, Carlo Pozzilli3, Vincenzo Brescia-Morra4, Paolo Gallo5, Luigi Maria Edoardo Grimaldi6, Massimo Filippi7, Giancarlo Comi G.2 and the MS Study Group-Italian Society of Neurology

Abstract

Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic.

Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age.

Results: 101 patients were included (69 females), mean age of MS onset 12.9 ± 2.7 years, mean age at NA initiation 14.7 ± 2.4 years. Mean treatment duration was 34.2 ± 18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3 ± 1.0 in the year prior to NA and decreased to 0.1 ± 0.3 (p < 0.001) at last NA infusion. Mean Expanded Disability Status Scale (EDSS) decreased from 2.6 ± 1.3 at initiation of NA to 1.8 ± 1.2 at the time of last visit (p < 0.001). At brain MRI, new T2 or Gd enhancing lesions were observed in 10/91 patients after 6 months, 6/87 after 12 months, 2/61 after 18 months, 2/68 after 24 months, 3/62 after 30 months, and 5/43 at longer follow up. At the time of last observation, 58 % of patients were free from clinical (relapses/increased EDSS) and/or MRI activity (new T2 or gadolinium-enhancing lesions). No relevant adverse events were recorded.

Discussion: NA was safe, well tolerated and very efficacious in the large majority of patients. Our data support the use of this medication in subjects with pediatric MS and an aggressive course.

Conclusions: A relevant reduction of relapse rate and EDSS was observed during NA treatment, compared to pre-treatment period. No evidence of disease activity (NEDA) occurred in 58 % of cases.

Background

Natalizumab (NA) is approved for the treatment of the relapsing form of multiple sclerosis (MS) for patients with inadequate response to first line treatments or with severe and active MS. First line medications, namely interferon beta (IFNB) and glatiramer acetate (GA), are the standard care of patients with pediatric MS (ped-MS) [1–3], however about 30 % of them are partial or non-responder to first line treatments requiring a shift to other disease modifying treatments (DMT) [4]. Some observational studies have shown that NA consistently reduces disease activity in patients with ped-MS [5–10]. No relevant adverse events have been reported up to now, the major concern remaining the possible occurrence of progressive multifocal leukoencephalopathy (PML) [11, 12]. This risk can now be evaluated by assessing the presence and the level of anti-JCV antibodies [13, 14].

NA is considered as a promising option for ped-MS patients with active MS and a poor response to IFNB and GA, with the limitation that data are not available in large cohorts of patients and after a long-term follow up [15]. We conducted this study to provide further pieces of information on this topic.

Methods

A registry was established in 2007 in Italy, within the MS Study Group of the Italian Society of Neurology, with the objective to collect all cases treated with NA before the age of 18 years and mandatorily included in...
the Italian Medicine Agency (AIFA) registry [5, 6]. Patients were eligible if they received at least one NA administration and had at least 3 months of observation. Details on study design (inclusion criteria, definition of relapse, neurological evaluation, NA administration, have been previously described [5, 6].

In the majority of cases brain MRI was performed every 6 months. The clinical records of 55 patients previously included in the database [6] have been updated in June 2014 when other 46 new cases had been included.

Anti-JCV antibodies in patients’ serum were assessed since the test *Stratify JCVTM* (performed at Unilabs, Copenhagen, Denmark) became available in Italy (March 2011).

The study was conducted in accordance with the International Conference on Harmonisation Guidelines of Good Clinical Practice and the Declaration of Helsinki. The protocol received approval from the ethical committee of the coordinating center (Ospedale di Gallarate, Sept. 2007) [5, 6]. Written informed consent was obtained from each patient participating in the study and her or his parents.

**Results**

One hundred-one patients were included (69 females), mean age (SD) of MS onset 12.9 ± 2.7 years, mean age (SD) at NA initiation 14.7 ± 2.4 years, mean treatment duration (SD) 34.2 ± 18.3 months. NA was administered at a standard dose of 300 mg every 28 days. Patients demographic data are reported in Table 1.

Sixty-six patients had been treated previously with immunosuppressants/ immunomodulators: 58 with IFNB, 9 with GA, 7 with immunosuppressants.

A total of 15 relapses were recorded in 9 patients during the whole treatment period; 8 of them occurred in the first year of treatment. The mean annualized relapse rate (SD) was 2.3 ± 1.3 in the year prior to NA and decreased to 0.1 ± 0.3 at the time of the last NA infusion (*p* < 0.001).

Mean EDSS (SD) decreased from 2.6 ± 1.3 at NA initiation to 1.8 ± 1.2 at the time of last visit (*p* < 0.001). EDSS remained stable in 27 cases, decreased by at least 0.5 point in 22 cases, by 1 point or more in 46 patients, and increased by 0.5 point in 5 patients and by > 0.5 in one (with increased T2 lesions at month 12).

MRI was performed within 1 month prior to starting NA in 93 patients, showing a mean number of 3.3 ± 4.4 Gd-enhancing lesions in 77 of them (82.8%). New lesions on T2-weighted sequences or Gd-enhancing lesions were observed in 10/91 (10.9%) patients at 6 months, 6/87 (6.9%) patients at 12 months (including one patient tested at month 9), 2/61 (3.3%) patients at 18 months, 2/68 (2.9%) patients at 24 months, 3/62 (4.8%) after 30 months, and 5/43 (10.6%) with a longer follow up.

Survival curves were used to calculate the frequency of patients free from clinical (no relapses, no EDSS increase) and/or MRI activity (no new T2, no Gd-enhancing lesions). At the time of the last observation, 58 % of cases showed no evidence of disease (clinical and MRI) activity (NEDA) (Fig. 1).

Serum anti-JCV antibodies were assessed in 100 patients, including 3 subjects not tested in our previous study; one discontinued therapy before the test became available. At baseline, the test was positive in 43/100 patients. During the follow up period the test was repeated in 45 subjects: 20 subjects remained negative, 18 subjects remained positive, 5 subjects shifted from the negative to the positive status, 2 vice versa (ratio not available at the time of the first assessment). The anti-JCV antibody index was determined in 21 subjects (<0.9 in 4 subjects; between 0.9 and 1.5 in 2 subjects; > 1.5 in 15 subjects).

A total of 66 clinical adverse events were observed in 36/101 patients (Table 2). All of them were mild, did not cause drug discontinuation and, if necessary, were treated according to normal standard of medical care. Mild hematological abnormalities (below toxicity level 1) were observed in 15/101 cases (Table 2): they resolved spontaneously and no intervention was required. Five patients were treated with NA before 10 years of age: transitory restlessness was recorded in one patient and transitory increase of WBC in another one.

At the time of the last update, in June 2014, NA was discontinued in 19 cases for various reasons: 2 for MS progression (after 9 and 30 infusions), 6 for anti-JCV Ab positivity (4 of them shifted to other DMT), 6 for parent/patient decision, other 4 patients suspended NA or shifted to other therapies but returned to NA after disease reactivation; one was lost a follow up. The mean time of withdrawal (SD) was 18.1 ± 14.2 months, during

---

**Table 1** Demographic and baseline clinical characteristics

| Characteristic                        | Mean (SD) |
|---------------------------------------|-----------|
| Age at MS onset (years)               | 12.9 (2.7) |
| Pre-NA disease duration (months)      | 25.6 (23.3) |
| Age at NA initiation (years)          | 14.7 (2.4)  |
| Weight (Kg)                          | 62.0 (13.3) |
| Height (cm)                          | 163.5 (12.3) |
| Number of relapses prior NA initiation| 4.0 (2.2)  |
| Number of relapses in the year prior NA initiation | 2.3 (1.3) |
| Number of Gd + MRI lesions prior NA initiation | 3.3 (4.4) |
| EDSS at NA initiation                 | 2.6 (1.3)  |
this period 10 patients relapsed (relapse rate 1.3 ± 1.2), 2 patients continued to worsen, 4 patients presented MRI reactivation, only 3 remained stable after 12–36 months.

Clinical data of patients included in our previous study (5) were updated after two additional years of follow up (mean follow up 47.2 ± 17.9 months). At the time of the last NA administration, after a mean of 42.9 ± 15.5 infusions, the mean EDSS was 1.9 ± 1.2 (mean initial score 2.7 ± 1.2), and only 4 patients relapsed, for a total of 5 relapses. Thirty-four patients continued to be free from clinical (neither relapses nor disability progression as measured by EDSS) and MRI activity (no new lesions on T2-weighted sequences and no Gd-enhancing lesions).

Discussion
The Italian registry of pediatric MS patients treated with NA was created seven years ago, within the Italian Multiple Sclerosis Study Group of the Italian Society of Neurology, to collect data on long-term safety and effectiveness of this medication in subjects before 18 years of age. Initially the use of NA was off-label and required the authorization by the Italian Agency of Drugs
In the present study we could confirm the good safety profile of NA in the pediatric population, with a frequency of adverse events similar to that reported in our previous study: they were mild in all cases, and, if necessary, they were treated according to usual medical procedures; in no patient NA had to be discontinued. The follow up of two additional years of the cohort of 55 subjects published in 2013 did not reveal the occurrence of other rare or unexpected events. Laboratory abnormalities were mild, confirming the good safety profile of NA in the pediatric population.

We could also confirm the excellent clinical response of NA, demonstrated by the impressive reduction of relapses during the exposure to NA therapy. Only 9 patients developed relapses, for a total of 15 relapses, 8 of them recorded in the first year of treatment. In the large majority of patients treatment with NA also induced an improvement of disability as measured by EDSS score, whereas only three patients worsened during the study. In two of them NA was stopped. Compared to the baseline score, EDSS was unchanged in 27 subjects, decreased by 0.5 or more in 68 subjects, increased by 0.5 or more in 6 subjects.

Trials are currently ongoing in the pediatric MS populations evaluating the effect of new medications (fingolimod, BG12, teriflunomide). Our experience shows that also the implementation of a clinical registry is an important tool to collect important information on

### Table 2 Clinical and laboratory adverse events

| Clinical adverse events                  | Number of subjects |
|-----------------------------------------|--------------------|
| Headache                                | 13                 |
| Upper respiratory disorders             | 9                  |
| Vertigo                                 | 7                  |
| Gastrointestinal disorders              | 5                  |
| Edema, itching, dermatitis              | 6                  |
| Herpes zoster                           | 4                  |
| Restlessness                            | 2                  |
| Urinary tract infections                | 3                  |
| Fatigue                                 | 4                  |
| Infections                              | 2                  |
| Menstrual disorders                     | 2                  |
| Ovarian cyst                            | 1                  |
| Sacral cyst                             | 1                  |
| Muscular pain                           | 1                  |
| Weight loss                             | 3                  |
| Depression                              | 1                  |
| Hypertension                            | 1                  |
| Tachycardia                             | 1                  |
| **Total**                               | **66**             |

| Laboratory abnormalities                | Number of subjects |
|-----------------------------------------|--------------------|
| Increased white blood cells             | 9                  |
| Increased bilirubin                     | 2                  |
| Increased ALT/AST                       | 2                  |
| Proteinuria                             | 1                  |
| Anemia                                  | 1                  |
| **Total**                               | **15**             |
long-term data about the efficacy and tolerability of new medications in ped-MS.

Conclusions
NAT was used in a cohort of patients before 18 years of age with an active form of MS, the majority of them with a poor response to first line treatments: this medication a consistently reduced relapse rate and disability. No evidence of disease activity (no relapses, no increase of the EDSS score, no new T2 lesions and no gadolinium enhancing lesions on brain MRI) was observed in 58 % of cases. NAT can be strongly considered as an option for patients with active ped-MS, particularly in cases negative for anti-JCV antibodies. No relevant adverse events were recorded and the medication was well tolerated.

Competing interests
AG serves on scientific advisory boards for Merck Serono and Teva Pharmaceutical Industries Ltd; received honoraria for speaking from Merck Serono, Biogen Idec, Bayer Schering Pharma, and Novartis; serves as a consultant for Novartis, receives research support from Sanofi Aventis, Biogen Idec and Merck Serono.
LM has received support to participate in National and International Congresses from Biogen Idec; Bayer Schering Pharma, Merck Serono, and Sanofi-Aventis.
CP serves on advisory boards for and received speaker honoraria from Sanofi Aventis, Biogen, Bayer Schering Pharma, Novartis, Teva, Merck Serono and research grants from Merck Serono, Sanofi Aventis, Novartis and Biogen. VBM has received funding for travel, speaker honoraria, and research support from Sanofi-Aventis, Bayer Schering Pharma, Merck Serono, and Biogen Idec. PG has received support to participate in National and International Congresses from Biogen Idec; Bayer Schering Pharma, Merck Serono, and Sanofi-Aventis.
LMEG has served on a scientific advisory board for Merck Serono; has received funding for travel or speaker honoraria from Merck Serono, Biogen Idec, Sanofi-Aventis, Bayer Schering Pharma and Savoly Pharmaceuticals, Inc.; has received institutional research support from Teva Pharmaceuticals Industries Ltd, Biogen Idec, Genzyme Corporation, Sanofi-Aventis, Merck Serono, Novartis and Eli Llc; has received research support from Merck Serono, Biogen Idec and Ministero della Salute di Italy.
MF serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen Idec, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves as a consultant to Bayer Schering Pharma, Biogen-Dompé, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on speakers’ bureaus for Bayer Schering Pharma, Biogen Idec, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and serves as a consultant to Novartis.
GC serves on scientific advisory boards for Bayer Schering Pharma, Merck Serono, Teva Pharmaceutical Industries Ltd, Sanofi Aventis, Novartis and Biogen-Idec; has received speaker honoraria from Teva Pharmaceutical Industries Ltd, Sanofi Aventis, Serono Sumposia International Foundation, Biogen-Idec, Merck Serono, Novartis, Bayer Schering and Sanofi Aventis.

Authors’ contributions
AG was involved in conception, design, coordination of the study, acquisition of data, elaboration and interpretation of results, elaboration and interpretation of results, drafting the manuscript: LM, CP, VBM, PG, LMEG, GC participated in study design, acquisition of data, interpretation of results, revised the manuscript, final approval. MF participated in study design, acquisition and interpretation of MRI data, interpretation of results, revision of the manuscript, final approval. All authors read and approved the final version of the manuscript.

Acknowledgements
For acquisition of data and revision of the manuscript: Annovazzi P, Bianchi A, (Gallarate), Bertolotto A. (Torino), Bortoloni F. (Vicenza), Calabrese M. (Verona), Capra C. (Chiari), Cargnelutti D. (Udine), Centonzee D. (Roma), Gallo A. (Napoli), Lanzillo R. (Napoli), Lus D. (Napoli), Patti F. (Catania), Prosperini C. (Roma), Provinciali L. (Ancona), Pucci E. (Macerata), Lugaresi A. (Chiari), Rinaldi F. (Padova), Rottoli MR. (Bergamo), Sarchielli P. (Perugia), Trojano M. (Bar), UcCELLI A. (Genova).
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author details
1 Multiple Sclerosis Study Center, Hospital of Gallarate, Via Pastori 4, 21013 Gallarate, Italy. 2 5th Department of Neurology, Hospital S. Raffaele, Milan, Italy. 3 S. Andrea Multiple Sclerosis Center, University of Rome La Sapienza, Rome, Italy. 4 MS Centre, Università degli Studi di Firenze, Florence, Italy. 5 Department of Neurology, University of Padua, Padua, Italy. 6 U.O.C. Neurologia, Fondazione Istituto San Raffaele “G.Giglio”, Cefalù, Italy.
7 Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neurosciences, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Received: 19 February 2015 Accepted: 18 September 2015
Published online: 25 September 2015

References
1. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13:936–48.
2. Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, et al. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 2013;80(11):1161–8.
3. Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010;16:1258–67.
4. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kurtz N, et al. Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Arch Neurol. 2011;68:437–44.
5. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Monra V, Bortoloni F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75:912–7.
6. Ghezzi A, Pozzilli C, Grimaldi LM, Miolo L, Brescia-Monra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19:1106–12.
7. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gätter J. Natalizumab use in pediatric multiple sclerosis, a retrospective study. Arch Neurol. 2008;65:1655–8. 
8. Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010;3:293–9.
9. Kornek B, Aboul-Enein F, Rostasy K, Milos R, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurology. 2013;70:469–75.
10. Arnal-García C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramíó-Torrenova L, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurology. 2013;17:50–4.
11. Buttukeven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7.
12. Kappos L, Bates D, Edan G, Erakosy M, Garcia-Merino A, Grigoridiadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10:745–58.
13. Gusek L, Lerner M, Bidler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295–303.
14. Plavina T, Subramaniam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–12.
15. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116–27.

16. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143–52.

17. Moiola L, Sangalli F, Martinelli V. Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiple sclerosis patients from Italy. Neurology Suppl. 2011;530(007):A375.